Successful Working Capital Optimization
The company successfully concluded its working capital optimization process, leading to improved operational cash generation without impacting sell-out or profitability.
Strong Revenue Growth
Net revenue increased by 16% to BRL 2.2 billion, driven by sell-out growth in retail, despite a 4% reduction in the institutional market.
High EBITDA Margin
Maintained an operational EBITDA margin of 34%, reaching nearly BRL 760 million, which is higher than previous quarters.
Record Operational Cash Flow
Achieved the highest operational cash flow in the company's history, with total cash generation of BRL 630 million, reducing net debt to 2.4x annualized EBITDA.
Strategic Product Launches
Focused on new product launches and market share gains, particularly in influenza medication, pain killers, gastric, cardiology, skin care, and hydration.